Pseudohypoparathyroidism (PHP) is a hereditary disorder characterized by an end-organ resistance for parathormone. PHP can be classified into different types by biochemical and phenotypic characteristics and the level of the defect in the hormone-receptor complex. PHP is described as Albright’s hereditary osteodystrophy (AHO) when a specific phenotype is present. We report a case of osteoma cutis in a 30-year-old woman with AHO. Successful treatment was obtained by debriding the lesion followed by split-thickness skin grafting.

Keywords:
Pseudohypoparathyroidism, Albright’s hereditary osteodystrophy, Osteoma cutis, Calcinosis cutis
1.
Potts JT: Diseases of the parathyroid gland and other hyper- and hypocalcemic disorders; in Braunwald E (ed): Harrison’s Principles of Internal Medicine, ed 11. New York, McGraw-Hill, 1987, pp 1886–1887.
2.
Walsh J, Fairley J: Calcifying disorders of the skin. J Am Acad Dermatol 1995;33:693–706.
3.
Eyre W, Reed W: Albright’s hereditary osteodystrophy with cutaneous bone formation. Arch Dermatol 1971;104:635–641.
4.
Lorette G, Valat J-P, Gatti Ph, Fetisoff F, Arbeille B, Boistard C, Moraine C: Ostéodystrophie héréditaire d’Albright avec ostéomes cutanés profus. Ann Dermatol Vénéréol 1984; 111:1073–1079.
5.
Barrett D, Breslau N, Wax M, Molinoff P, Downs R: New form of pseudohypoparathyroidism with abnormal catalytic adenylate cyclase. Am J Physiol 1989;257:E277–283.
6.
Prendiville J, Lucky A, Mallory S, Mughal Z, Mimouni F, Langman C: Osteoma cutis as a presenting sign of pseudohypoparathyroidism. Pediatr Dermatol 1992;9:11–18.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.